Evidence map›Paper›PMID 35589534›Full record

ReviewCanadian journal of diabetes2022

Islet Biology During COVID-19: Progress and Perspectives.

Theodore Dos Santos, Maria Galipeau, Amanda Schukarucha Gomes, Marley Greenberg, Matthew Larsen, Daniel Lee, Jasmine Maghera, Christina Marie Mulchandani, Megan Patton, Ineli Perera and 11 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Canadian journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Theodore Dos SantosAlberta Diabetes Institute & Department of Pharmacology, Li Ka Shing Centre for Health Research Innovation, University of Alberta, Edmonton, Alberta, Canada.
Maria GalipeauDepartment of Molecular Biology, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada; Institut de recherches cliniques de Montréal, Cardiometabolic Disease Centre, Montréal, Québec, Canada.
Amanda Schukarucha GomesAlberta Diabetes Institute & Department of Pharmacology, Li Ka Shing Centre for Health Research Innovation, University of Alberta, Edmonton, Alberta, Canada.
Marley GreenbergToronto General Hospital, Toronto, Ontario, Canada.
Matthew LarsenToronto General Hospital, Toronto, Ontario, Canada.
Daniel LeeDepartment of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
Jasmine MagheraAlberta Diabetes Institute & Department of Pharmacology, Li Ka Shing Centre for Health Research Innovation, University of Alberta, Edmonton, Alberta, Canada.
Christina Marie MulchandaniToronto General Hospital, Toronto, Ontario, Canada.
Megan PattonToronto General Hospital, Toronto, Ontario, Canada.
Ineli PereraDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Kateryna PolishevskaAlberta Diabetes Institute and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Seeta RamdassToronto General Hospital, Toronto, Ontario, Canada.
Kasra ShayeganpourAlberta Diabetes Institute and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Kiano VafaeianToronto General Hospital, Toronto, Ontario, Canada.
Kyle Van AllenDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Yufeng WangUniversity Health Network, Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Tom WeiszToronto General Hospital, Toronto, Ontario, Canada.
Jennifer L EstallDepartment of Molecular Biology, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada; Institut de recherches cliniques de Montréal, Cardiometabolic Disease Centre, Montréal, Québec, Canada.
Erin E MulvihillEnergy Substrate Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, Ontario, Canada.
Robert A ScreatonSunnybrook Research Institute, Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada. Electronic address: robert.screaton@sri.utoronto.ca.
Diabetes Action Canada and the Canadian Islet Research and Training Network
Toronto General Hospital · CAUniversity of Alberta · CACarleton University · CAMontreal Clinical Research Institute · CASunnybrook Health Science Centre · CAUniversity Health Network · CAUniversity of Calgary · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus-2019 (COVID-19) pandemic has had significant impact on research directions and productivity in the past 2 years. Despite these challenges, since 2020, more than 2,500 peer-reviewed articles have been published on pancreatic islet biology. These include updates on the roles of isocitrate dehydrogenase, pyruvate kinase and incretin hormones in insulin secretion, as well as the discovery of inceptor and signalling by circulating RNAs. The year 2020 also brought advancements in in vivo and in vitro models, including a new transgenic mouse for assessing beta-cell proliferation, a "pancreas-on-a-chip" to study glucose-stimulated insulin secretion and successful genetic editing of primary human islet cells. Islet biologists evaluated the functionality of stem-cell-derived islet-like cells coated with semipermeable biomaterials to prevent autoimmune attack, revealing the importance of cell maturation after transplantation. Prompted by observations that COVID-19 symptoms can worsen for people with obesity or diabetes, researchers examined how islets are directly affected by severe acute respiratory syndrome coronavirus 2. Herein, we highlight novel functional insights, technologies and therapeutic approaches that emerged between March 2020 and July 2021, written for both scientific and lay audiences. We also include a response to these advancements from patient stakeholders, to help lend a broader perspective to developments and challenges in islet research.

Indexed as

COVID-19Diabetes Mellitus, Type 1Islets of LangerhansIslets of Langerhans TransplantationAnimalsBiologyHumansInsulinMiceInsulinCOVID-19diabètediabetesencapsulationîlotsinsulin secretionisletsécrétion d’insulinetransplantation

Identifiers

PMID35589534
PMCPMC8608413
OpenAlexW3215462417

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.